Our top pick for
Inozyme Pharma, Inc is a biotechnology business based in the US. Inozyme Pharma shares (INZY) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||USD$25.93|
|52-week range||USD$16.1 - USD$31.65|
|50-day moving average||USD$24.2606|
|200-day moving average||USD$24.2975|
|Wall St. target price||USD$36.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.1071|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||1.73%|
|1 month (2020-12-16)||8.81%|
|3 months (2020-10-16)||11.82%|
|6 months (2020-07-13)||N/A|
|1 year (2020-01-13)||N/A|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$609.6 million|
TTM: trailing 12 months
There are currently 340,891 Inozyme Pharma shares held short by investors – that's known as Inozyme Pharma's "short interest". This figure is 52.8% down from 721,615 last month.
There are a few different ways that this level of interest in shorting Inozyme Pharma shares can be evaluated.
Inozyme Pharma's "short interest ratio" (SIR) is the quantity of Inozyme Pharma shares currently shorted divided by the average quantity of Inozyme Pharma shares traded daily (recently around 31622.54174397). Inozyme Pharma's SIR currently stands at 10.78. In other words for every 100,000 Inozyme Pharma shares traded daily on the market, roughly 10780 shares are currently held short.
However Inozyme Pharma's short interest can also be evaluated against the total number of Inozyme Pharma shares, or, against the total number of tradable Inozyme Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inozyme Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Inozyme Pharma shares in existence, roughly 10 shares are currently held short) or 0.0146% of the tradable shares (for every 100,000 tradable Inozyme Pharma shares, roughly 15 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Inozyme Pharma.
Find out more about how you can short Inozyme Pharma stock.
We're not expecting Inozyme Pharma to pay a dividend over the next 12 months.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Everything we know about the Bakkt Holdings IPO, plus information on how to buy in.
Everything we know about the Dream Finders Homes Inc IPO, plus information on how to buy in.
Everything we know about the Q BioMed Inc IPO, plus information on how to buy in.
Everything we know about the Faraday Future IPO, plus information on how to buy in.
Everything we know about the TELUS International Inc IPO, plus information on how to buy in.
Everything we know about the Interior Logic Group Holdings LLC IPO, plus information on how to buy in.
Everything we know about the Evaxion Biotech IPO, plus information on how to buy in.
Everything we know about the ON24 Inc IPO, plus information on how to buy in.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.